- In June 2023, Croda, Inc. announced the initiation of constructing a new manufacturing facility in Pennsylvania, U.S. This strategic investment is aimed at enhancing their production capabilities, ensuring they can effectively meet the evolving demands of the industry. The new facility is expected to strengthen Croda’s position in the market by increasing its manufacturing capacity and improving operational efficiency in response to consumer and industry needs
- In September 2022, Nutriventia, a global player in connecting suppliers and buyers of food, health, and natural ingredients, launched Prolanza, a sustained-release ashwagandha (Withania somnifera) extract. Prolanza is designed to provide prolonged stress management support, offering a new, cutting-edge solution for stress relief. The root-only extract represents an innovative approach to delivering the benefits of ashwagandha over an extended period, meeting consumer demands for functional ingredients
- In February 2022, Biohaven Pharmaceutical Holding Company Ltd., in collaboration with Pfizer Inc., expressed confidence in the potential of rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The companies have endorsed the 75 mg dose of rimegepant, available as an orally dissolving tablet, for marketing authorization. This medication is expected to offer significant advancements in migraine treatment by targeting the underlying causes and providing better relief for patients suffering from this condition
- In February 2021, DuPont completed its merger of the Nutrition & Biosciences Business with International Flavors & Fragrances, a move that significantly expanded its product offerings. The inclusion of Aquacoat products into DuPont’s portfolio enhances its ability to provide diverse and innovative solutions. This merger allowed DuPont to cater to a broader range of industry needs, further strengthening its position in the market and its capacity to meet customer demands in nutrition and biosciences
Frequently Asked Questions
The market is segmented based on Segmentation, By Route of Administration (Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others), Mode (Over-the-Counter and Prescription), Distribution Channel (Hospital Pharmacies and Online Pharmacies) – Industry Trends and Forecast to 2032
.
The Global Sustained Release Drugs Market size was valued at USD 13.29 USD Billion in 2024.
The Global Sustained Release Drugs Market is projected to grow at a CAGR of 8.06% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
